Mira Pharmaceuticals (MIRA) EPS (Basic) (2024 - 2025)
Mira Pharmaceuticals (MIRA) posted EPS (Basic) of -$0.25 for Q4 2025, up 78.55% sequentially from -$1.18 in Q3 2025, and down 62.52% YoY from -$0.67 in Q4 2024.
Mira Pharmaceuticals (MIRA) EPS (Basic) (2024 - 2025) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 2 years of EPS (Basic) data on file, last reported at -$0.25 in Q4 2025.
- Quarterly EPS (Basic) fell 62.52% year-over-year to -$0.25 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.21 (down 320.66% YoY) and the FY2025 annual result came in at -$1.35, down 165.61% from the prior year.
- EPS (Basic) grew to -$0.25 in Q4 2025 per MIRA's latest filing, from -$1.18 in the prior quarter.
- The five-year high for EPS (Basic) was -$0.14 in Q3 2024, with the low at -$1.18 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 8.27 |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.17 |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 0.39 |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 121.99 |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -2.35 |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 3.37 |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 1.63 |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 0.00 |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | -0.25 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.25 |
| Sep 30, 2025 | -1.18 |
| Dec 31, 2024 | -0.16 |
| Sep 30, 2024 | -0.14 |